Naratriptan

ATC N02CC02 · 5 markets · 47 records

Naratriptan 5 markets · 47 records Forms

GB 27 records · 1 strengths

2.5 mgtabletNaramig 2.5mg tablets+1__no_trade__ also in US·CA·AU +1

US 8 records · 2 strengths

2.5 mgtabletNo trade name also in GB·CA·AU +1
1 mgtabletNo trade name also in CA

CA 5 records · 2 strengths

2.5 mgtabletAPO-NARATRIPTAN+2SANDOZ NARATRIPTAN、TEVA-NARATRIPTAN also in GB·US·AU +1
1 mgtabletAPO-NARATRIPTAN+1TEVA-NARATRIPTAN also in US

AU 3 records · 2 strengths

2.5 mgtabletNaramig 2.5mg tablets also in GB·US·CA +1

Records without a stated strength · 1 Naramig 2.5mg tablets、Naramig Migraine

ES 1 records · 1 strengths

2.5 mgtabletNaramig 2.5mg tablets also in GB·US·CA +1

Side-by-side table

Strength / form / release	US	GB	CA	AU	ES
2.5 mg tablet	No trade name	No trade name Naramig 2.5mg tablets	APO-NARATRIPTAN SANDOZ NARATRIPTAN TEVA-NARATRIPTAN	Naramig 2.5mg tablets	Naramig 2.5mg tablets
1 mg tablet	No trade name	not recorded	APO-NARATRIPTAN TEVA-NARATRIPTAN	not recorded	not recorded
not disclosed unknown	not recorded	not recorded	not recorded	Naramig 2.5mg tablets Naramig Migraine	not recorded

Scroll horizontally for more markets →

Each country column shows the locally registered trade names — not translations.

“not disclosed” means the source does not publish the strength — it does not mean the product has none.

Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.

Back to the list

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.